Nonhematologic manifestations of FPDMM. (A) The prevalence of allergic/immunologic symptoms in 45 consecutive patients prospectively evaluated by the NIH allergy/immunology clinic team. (B) The prevalence of gastrointestinal (GI) symptoms in 30 consecutive patients prospectively evaluated by the NIH GI clinical team. The number of patients with FPDMM is compared with the prevalence in the NIH All of Us database in both panels A and B. (C) Pulmonary function testing results for patients. The y-axis is percentage of reference value. Horizontal bars indicate mean and standard deviation. DLCO adj, adjusted diffusing capacity for carbon monoxide; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; GERD, gastroesophageal reflux disease; RV, residual volume; TLC, total lung capacity.